Floatz logo

Vyxeos

Leukemia

Children's Hospital Medical Center, CincinnatiPhase 1Active
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

124 Active assets in the Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
ASPARAGINASE
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3BB
THIOGUANINE ANHYDROUS
Incyte Corporation
Phase 3BB
Idarubicine
Affiliated Hospital of Nantong University
Phase 3BB
Daunorubicin
Richard Stone, MD
Phase 3BB

View all 50 →

Same molecule, other indications

Vyxeos is also rated in:

myelodysplastic syndromeDormant
B
Indicative ·
57 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
56 / 100
View asset →
childhood acute myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →